With that in mind, theres been growing interest in Delta Sleep-Inducing Peptide (DSIP) as a potential sleep solution
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials, Diabetes and Metabolism Journal (2019) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA (2022) Once-weekly semaglutide in adults with overweight or obesity, The New England Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022) Patient assistance program, Novo Nordisk APC: Find a compounder, Alliance for Pharmacy Compounding (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
What are Ozempic and Wegovy used for
[Ref] Nervous system Very common (10% or more): Sleepiness (up to 13.74%) Common (1% to 10%): Headache Rare (0.01% to 0.1%): Convulsion, tremor Frequency not reported : Anticholinergic activity, central nervous system (CNS) depression, drowsiness, incoordination, involuntary motor activity, psychomotor impairment, stimulation Postmarketing reports : Dizziness, dyskinesia, dystonia, paresthesia, sedation, seizures, syncope [Ref] Other Common (1% to 10%): Tiredness Frequency not reported : Antimuscarinic effects, lassitude Postmarketing reports : Asthenia, malaise, pyrexia, sudden death [Ref] Gastrointestinal Common (1% to 10%): Dry mouth Postmarketing reports : Constipation, diarrhea, nausea, vomiting [Ref] Cardiovascular Frequency not reported : QT prolongation, Torsade de Pointes Postmarketing reports : Cardiac arrest, cardiac arrhythmias, edema, hypotension, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia [Ref] Hypersensitivity Frequency not reported : Hypersensitivity reaction Postmarketing reports : Allergic reaction, anaphylactic shock, angioedema, hypersensitivity [Ref] Respiratory Frequency not reported : Respiratory depression Postmarketing reports : Bronchospasm [Ref] Dermatologic Postmarketing reports : Acute generalized exanthematous pustulosis (AGEP), bullous condition (pemphigoids, toxic epidermal necrolysis), dermatitis, erythema, erythema multiforme, fixed drug eruptions, increased sweating, maculopapular rash, pruritus, rash, Stevens-Johnson syndrome, urticaria [Ref] Psychiatric Postmarketing reports : Aggression, agitation, confusion, depression, disorientation, hallucination, insomnia, tics [Ref] Genitourinary Postmarketing reports : Dysuria, enuresis, urinary retention [Ref] Ocular Postmarketing reports : Accommodation disorder, blurred vision, oculogyric crisis [Ref] Hepatic Postmarketing reports : Hepatitis, liver function tests abnormal [Ref] Hematologic Postmarketing reports : Thrombocytopenia [Ref] Metabolic Postmarketing reports : Weight gain [Ref] References 1
When used in medication form, such as semaglutide or liraglutide, GLP-1 can assist with weight loss by making you feel fuller for longer and stabilizing blood sugar levels
